Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 13, 2005. The report serves as a notification of transactions involving directors or persons discharging managerial responsibility, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific transaction notification rather than general financial performance.
Material Changes
A material change occurred within the US Retirement Savings Plan ("The Plan") due to a re-valuation of the cash element of the notional investment held in GSK Ordinary Share ADRs. This resulted in a decrease in the notional allocation of Ordinary Share ADRs on September 9, 2005, at a price of $50.55 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. The unusual item noted is the specific transaction notification for Mr. R Greig, reported in accordance with Disclosure Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- The filing reports a decrease in notional ADR allocation for Mr. R Greig on September 9, 2005.
- The transaction price was $50.55 per share.
- The notification was issued by the Plan Administrators on September 12, 2005.
- This report does not contain quarterly or annual financial results.